Circular permuteins of flt3 ligand
First Claim
Patent Images
1. A human flt-3 receptor agonist polypeptide, comprising a modified flt-3 ligand amino acid sequence selected from the group consisting of:
- (a) the sequence of SEQ ID NO;
144; and
(b) a polypeptide comprising residues 1-132 of SEQ ID NO;
144;
wherein said modification comprises the linear rearrangement of the sequences of (a) or (b);
wherein the N-terminus is joined to the C-terminus directly or through a linker capable of joining the N-terminus to the C-terminus and new C- and N-termini are created between the amino acid residue pairs of SEQ ID NO;
144 selected from the group consisting of;
28-29, 29-30, 30-31, 31-32, 32-33, 34-35, 36-37, 37-38, 38-39, 40-41, 41-42, 42-43, 64-65, 65-66, 66-67, 86-87, 88-89, 89-90, 90-91, 91-92, 92-93, 93-94, 94-95, 95-96, 96-97, 97-98, 98-99, 99-100, 100-101, 101-102, and 102-103; and
wherein optionally said flt-3 receptor agonist polypeptide is immediately preceded by (methionine−
1), (alanine−
1) or (methionine−
2, alanine−
1).
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed are novel flt-3 receptor agonist proteins, DNAs which encode the flt-3 receptor agonist proteins, methods of making the flt-3 receptor agonist proteins and methods of using the flt-3 receptor agonist proteins.
28 Citations
11 Claims
-
1. A human flt-3 receptor agonist polypeptide, comprising a modified flt-3 ligand amino acid sequence selected from the group consisting of:
-
(a) the sequence of SEQ ID NO;
144; and
(b) a polypeptide comprising residues 1-132 of SEQ ID NO;
144;
wherein said modification comprises the linear rearrangement of the sequences of (a) or (b);
wherein the N-terminus is joined to the C-terminus directly or through a linker capable of joining the N-terminus to the C-terminus and new C- and N-termini are created between the amino acid residue pairs of SEQ ID NO;
144 selected from the group consisting of;28-29, 29-30, 30-31, 31-32, 32-33, 34-35, 36-37, 37-38, 38-39, 40-41, 41-42, 42-43, 64-65, 65-66, 66-67, 86-87, 88-89, 89-90, 90-91, 91-92, 92-93, 93-94, 94-95, 95-96, 96-97, 97-98, 98-99, 99-100, 100-101, 101-102, and 102-103; and
wherein optionally said flt-3 receptor agonist polypeptide is immediately preceded by (methionine−
1), (alanine−
1) or (methionine−
2, alanine−
1).- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
GlyGlyGlySer SEQ ID NO;
38;
GlyGlyGlySerGlyGlyGlySer SEQ ID NO;
39;
GlyGlyGlySerGlyGlyGlySerGlyGlyGlySer SEQ ID NO;
40;
SerGlyGlySerGlyGlySer SEQ ID NO;
41;
GluPheGlyAsnMet SEQ ID NO;
42;
GluPheGlyGlyAsriMet SEQ ID NO;
43;
GluPheGlyGlyAsnGlyGlyAsnMet SEQ ID NO;
443GlyGlySerAspMetAlaGly SEQ ID NO;
45;
SerGlyGlyAsnGly SEQ ID NO;
46;
SerGlyGlyAsnGlySerGlyGlyAsnGly SEQ ID NO;
47;
SerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGly SEQ ID NO;
48;
SerGlyGlySerGlySerGlyGlySerGly SEQ ID NO;
49;
SerGlyGlySerGlySerGlyGlySerGlySerGlyGlySerGly SEQ ID NO;
50;
GlyGlyGlySerGlyGly SEQ ID NO;
51;
GlyGlyGlySerGlyGlyGly SEQ ID NO;
52;
GlyGlyGlySerGlyGlyGlySerGlyGly SEQ ID NO;
53;
GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly SEQ ID NO;
54;
GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SEQ ID NO;
55;
GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGly SEQ ID NO;
56;
GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGly SEQ ID NO;
148;
ProProProTrpSerProArgProLeuGlyAlaThrAlaProThrAlaGly GlnProProLeu SEQ ID NO;
149;
ProProProTrpSerProArgProLeuGlyAlaThrAlaProThr SEQ ID NO;
150; and
ValGluThrValPheHisArgValSerGlnAspGlyLeuLeuThrSer SEQ ID NO;
151.
-
-
3. The flt-3 receptor agonist polypeptide, as recited in claim 1, selected from the group consisting of;
-
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMETGlu ArgLeuLysThrValAlaGlySerLysMETGlnGlyLeuLeuGluArgValAsnThrGlu IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgpheValGln ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuSerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO;
8;
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMETGlu ArgLeuLysThrValAlaGlySerLysMETGlnGlyLeuLeuGluArgValAsnThrGlu IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGln SEQ ID NO;
9;
AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMETGlu ArgLeuLysThrValAlaGlySerLysMETGlnGlyLeuLeuGluArgValAsnThrGlu IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgpheValGln ThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuSerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGln SEQ ID NO;
10;
AlaSerLysMETGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGly SerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerPro IleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr ProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMETGluArgLeuLysThrValAlaGly SEQ ID NO;
11;
AlaSerLysMETGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnphe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGly SerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspphe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMETGluArgLeuLysThrValAlaGly SEQ ID NO;
12AlaSerLysMETGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGly ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMETGluArgLeu LysThrValAlaGly SEQ ID NO;
13;
AlaProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeu GluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsn GlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMETGluArgLeuLysThrValAlaGlySerLysMETGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO;
14;
AlaProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeu GluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsn GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMETGluArg LeuLysThrValAlaGlySerLysMETGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnPro SEQ ID NO;
15;
AlaProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeu GluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCys GlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMETGluArgLeuLysThrValAla GlySerLysMETGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnPro SEQ ID NO;
16;
AlaAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln SEQ ID NO;
31;
AlaAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgvalAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCys LeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln ProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal SEQ ID NO;
32;
AlaValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnIle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr SEQ ID NO;
33;
AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPhevalGlnThrAsnIleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPro IleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr ProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO;
34;
AlaProProSerCysLeuArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeu GluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO;
35;
AlaArgPheValGlnThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln ProAspSerSerThrLeuGlyGlyGlySerGlyClyGlySerGlyGlyGlySerGlyGly GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeu SEQ ID NO;
36;
AlaThrAsnIleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro TrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer ThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGln SEQ ID NO;
37.
-
-
4. A nucleic acid molecule, comprising a sequence encoding the flt-3 receptor agonist polypeptide of claim 1.
-
5. A nucleic acid molecule, comprising a sequence encoding the flt-3 receptor agonist polypeptide of claim 2.
-
6. A nucleic acid molecule, comprising a sequence encoding the flt-3 receptor agonist polypeptide of claim 3.
-
7. A nucleic acid molecule, comprising a sequence encoding the flt-3 receptor agonist polypeptide of claim 6, selected from the group consisting of:
-
GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCTGGAGGTAACGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAAC CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAG SEQ ID NO;
113;
GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCAGGCGGTAACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTT CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO;
114;
GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCTGGCGGCAACGGCACCCAGGACTGCTCCTTCCAACACAGCCCCAT CTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO;
115;
GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGTAACGGATCCGGTGGCA ATGGGAGCGGCGGAAATGGAACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCT TCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCT GCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGG SEQ ID NO;
116;
GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGTAACGGATCCGGAGGTA ATGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTC GCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGT CACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGC GGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO;
117;
GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGTCTGGCGGCAACGGCACGCAGGACT GCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAA CCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCAC AGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO;
118;
GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCTGGAGGTAACGGCAGTGGTGGCAATGGGAGCGGTGGAAATGGAAC CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGT CCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGA TGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAA TGTGCCTTTCAGCCC SEQ ID NO;
119;
GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCAGGCGGTAACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTT CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG GACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTG GATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGG AGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO;
120;
GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCTGGCGGCAACGGCACGCAGGACTGCTCCTTCCAACACAGCCCCAT CTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGC GGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAA GACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGG AGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO;
121;
GCCGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCCTGCCGGGG GCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGC TGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACA TCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGAT CACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCC AGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG TGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO;
136;
GCCGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCC TGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGG AGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTC CCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCA GGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAAC ACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCT GCTTCAAGATTACCCAGTCACCGTG SEQ ID NO;
137;
GCCGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATAC ACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAG CCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGG TGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCT CCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACT SEQ ID NO;
138;
GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCcCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACAT CTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAA CCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCA GGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGC AGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGAT GGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO;
139;
GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGG AGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTC CCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCA GGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAAC ACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCT GCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGC GGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTG TCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT TGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO;
140;
GCCCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGC TGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCT GCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCT CCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGA rTGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGC CTTTCAGCCCCCCCCCAGCTGTCTT SEQ ID NO;
142;
GCCACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGA AGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCC CGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA GGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTG TCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGC CTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCC CCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO;
143.
-
-
8. A method of producing a flt3 receptor agonist polypeptide comprising:
- growing under suitable nutrient conditions, a host cell transformed or transfected with a replicable vector comprising said nucleic acid molecule of claim 4, 5, 6 or 7 in a manner allowing expression of said flt3 receptor agonist polypeptide and recovering said flt3 receptor agonist polypeptide.
-
9. A composition comprising;
- a polypeptide of claim 1, 2, or 3 and a pharmaceutically acceptable carrier.
-
10. A composition comprising;
- a polypeptide of claim 1, 2, or 3 a factor selected from the group consisting of;
a colony stimulating factor, a cytokine, a lymphokine, an interleukin, and a hematopoietic growth factor; and
a pharmaceutically acceptable carrier.
- a polypeptide of claim 1, 2, or 3 a factor selected from the group consisting of;
-
11. The composition according to claim 10 wherein said factor is selected from the group consisting of:
- GM-CSF, G-CSF, c-mpl ligand, M-CSF, IL-1, IL4, IL-2, IL-3, IL-5, IL-6, IL-7, IL-8, L-9, IL-10, IL-11, IL-12, IL-13, IL-15, LIF, flt3 ligand, and EPO.
Specification